In 2018, the Food and Drug Administration (FDA) approved the combination of anti-PD-1 (pembrolizumab) with chemotherapy drugs (pemetrexed and carboplatin) to treat metastatic NSCLC [6]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.